Andrew Abrams is a Partner at New Science Ventures, a venture capital firm focused on building companies that address large unmet needs in the Life Sciences and Information Technology sectors.
Prior to joining New Science Ventures, Andrew was an Associate in J.P. Morgan’s healthcare investment banking practice where he focused on mergers and acquisitions and debt and equity transactions in Europe and the U.S. He advised a wide array of clients spanning the biotechnology, pharmaceutical, medical device, diagnostic and healthcare service sub-sectors. He has also served as an analytical laboratory manager at Monsanto and as business development lead at an early-stage life science tools business, miniPCR bio.
Andrew received his B.A., M.A. and M.Sci. degrees in Natural Sciences and Biochemistry from the University of Cambridge where he was awarded the Richard Perham Scholarship for the most distinguished performance. He also participated in Cambridge’s year-long exchange program with the Massachusetts Institute of Technology. In addition, he holds an M.B.A. from Harvard Business School.
Prior to joining ProterixBio, Brett Masters served as VP of Engineering at Midé Technology Corporation, now a Hutchinson Company. Dr. Masters joined Midé in early 1997 and the role of VP of Engineering in 1998.
Dr. Masters’ educational background includes a Doctor of Science, a Master of Science, and a Bachelor of Science in Aeronautics and Astronautics from the Massachusetts Institute of Technology. Prior to this, Dr. Masters attended the University of Auckland in his homeland of New Zealand.
Dr. Masters has received several awards including the NASA OAST “Commendation for Technology Excellence” for the Middeck 0-Gravity Dynamics Experiment as well as the 1994 ASME Structures and Materials Award for work presented on “Global Structure Modeling Using Force-State Component Identification”. He also won the James Mean Memorial Award (MIT) for outstanding contribution in the design of a high-flying aircraft for sampling of ozone in the Antarctic Circle as well as the Luis de Florez Award (MIT) for design ingenuity in developing, building and testing a v-shaped hydrofoil for windsurfing.
Dr. Colón brings over 25 years’ experience in biopharma, genomics, diagnostics, health care, drug delivery and industrial biotechnology.
In addition to her role at ProterixBio, she is President and CEO at InCarda Therapeutics, a biopharmaceutical company pioneering a novel approach of treating cardiovascular conditions and diseases by the inhalation route. She also serves on the board of CareDx (NASDAQ:CDNA), and previously served on the boards of Paradigm Diagnostics (acquired by Exact Sciences (NASDAQ:EXAS), PerceptiMed and Cocoon Biotech, and on the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University.
Previously, she was founding President of the Industrial Products Division and Senior Vice President at Intrexon Corporation (NYSE:XON) where she established a new division focused on leveraging synthetic biology for bioindustrial applications such as biofuels and renewable chemicals and was a key contributor to the company’s $100M Series E raise.
Prior to Intrexon, she was head of Clinical Operations for Gilead Sciences (Nasdaq:GILD), where she was responsible for global execution of clinical trials. At Gilead, she also created and led both the Alliance Management and Commercial Strategic Planning groups. Prior to Gilead, she was VP, Corporate Planning at Affymetrix (acquired by ThermoFisher (NYSE:TMO), where she was responsible for strategic planning and project management and where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics.
Earlier in her career, Grace was a consultant at McKinsey & Company, where she served clients in healthcare, high tech, consumer goods and venture capital. She was also an engineer with Merck & Co. in France and in Rahway, NJ.
Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow and recipient of multiple NIH training grants. She also holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.
Charlie is a seasoned financial professional with experience growing companies in fast-paced environments, improving financial performance of troubled enterprises and structuring complex transactions. His areas of expertise include design and implementation of accounting systems, budgets, forecasts and management reporting tools, capital fundraising, expense management and executing business plans to profitability.
Charlie was the Chief Financial Officer of The Merallis Company, a technology services firm located in Rocky Hill, CT, where he managed all aspects of accounting, finance and capital fundraising. Charlie defined financial reporting structures across this 90-member organization into 8 key functional departments to improve autonomy and fiscal efficiency. He revised the corporate financial plan and reduced projected expenses by 30% while maintaining expected revenue growth. Charlie also negotiated and managed all aspects of $9,500,000 in equity capital fund-raising to finance national sales and marketing initiatives.
Prior to Merallis, Charlie was a founding management member of PQC, Inc., a management services company that raised $50M in private capital, grew to 1,200 employees in 3 states and $80 million in revenue. As a Vice President at PQC, Charlie managed various aspects of finance and operations for the Company.
Charlie also founded Medical Claims Management (MCM), a practice reimbursement management and consulting firm focused on profitability improvement and operations management. MCM achieved profitability within the first 12 months of operations with $10M of revenues under management. Charlie curtailed his day-to-day involvement in this enterprise to join the founding management team of PQC and ultimately sold his interests in MCM.
Earlier in his career, Charlie worked as a Senior Consultant for Price Waterhouse and as Senior Accountant for Deloitte & Touche. He is a CPA, has a B.S. in Accountancy an A.S. in Management from Bentley College and an M.M. in Finance and Business Policy from the J.L. Kellogg School at Northwestern University. Charlie currently resides in Needham, MA with his wife and two children.